Cells become malignant due to accumulation of specific mutations. New mutations occur in cells permanently throughout their lifespan. Normally, the immune system recognizes and destroys cancer cells but this process is not always effective. Cancer cells do not senesce or undergo apoptosis because both processes are disrupted in malignant cells; Instead they become capable of uncontrolled growth and division, and gain the ability to invade neighboring tissues.
One of the strategies used in cancer therapy is to improve the identification of cancer cells by immune system. This approach was used in the development of a new drug Mobilan produced by Panacela company with the support of Cleveland BioLabs and RUSNANO. The mechanism of action of the drug is based on delivery to the tumor cells of two genes encoding flagellin — a structural protein of bacterial flagellum. The genes are delivered to tumor cells by a non-pathogenic adenoviral vector particle. Flagellin is a familiar antigen for the immune system and once its genes reach the tumor cells the immune response against the malignant tissue is induced: TLR5, the toll-like receptor, recognizes flagellin and triggers the production of cytokines which attract and activate immune cells. The exact mechanism of the activation of immune system by Mobilan and the possibility to use the flagellin-TLR5 based scheme in therapy of some non-oncogenic disorders are still under investigation. Our infografics demonstrate an overview of Mobilan possible mechanism of action.


RUSNANO (Panacela & Cleveland BioLabs)

Date: Sep 02, 2013


Congratulation for your very succesful 3D HIV model
Prof. Françoise BARRÉ-SINOUSSI, Nobel Prize in Medicine 2008, Pasteur Institute, Paris, France
Project Inquiry

Tell us how to reach you and we’ll contact you shortly

Your request was sent. Thank you for your interest!